SynthesisEndocrine2026
Impact of empagliflozin on liver fat reduction in type 2 diabetes and NAFLD: A systematic review and meta-analysis.
Synthesis in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-alcoholic fatty liver disease (NAFLD) and type 2 Diabetes Mellitus are the major causes of significant mortality and morbidity. NAFLD and type 2 diabetes have common risk factors. SGLT-2 inhibitors are believed to have a beneficial effect on liver fat in patients with NAFLD and type 2 diabetes. However, there are limited data available on this aspect of empagliflozin use. Thus, we aimed to compare the impact of empagliflozin on liver fat reduction in type 2 diabetes and NAFLD.
methodsA comprehensive search of databases like PubMed, Google Scholar, and Cochrane Library was done. In the end, a detailed analysis was performed on a total of 6 finalized studies, all of which were randomized controlled trials. This comprehensive analysis consisted of a cohort of 589 Individuals.
resultsA total of six studies were included. Primary outcomes assessed were MRI-PDFF, AST, ALT, HOMA-IR and total bilirubin. Empagliflozin significantly reduced liver fat compared to placebo, with a pooled standardized mean difference (SMD) of −0.43 (95% CI: −0.82 to −0.04; p = 0.03; I² = 0%). AST also showed a significant reduction (SMD = −0.41; 95% CI: −0.66 to −0.16; p = 0.001; I² = 34%), while ALT showed a non-significant trend favoring empagliflozin (SMD = −0.60; 95% CI: −1.25 to 0.04; p = 0.07) with high heterogeneity (I² = 91%). No significant effects were observed for HOMA-IR (SMD = −0.10; 95% CI: −0.43 to 0.24; p = 0.57) or total bilirubin (SMD = −0.04; 95% CI: −1.16 to 1.08; p = 0.94). Among secondary outcomes, only liver segment VIII showed a significant benefit (SMD = −0.97; 95% CI: −1.68 to −0.25; p = 0.008), though heterogeneity remained substantial (I² = 79%). No significant changes were found in total cholesterol.
conclusionMRI-PDFF showed that empagliflozin significantly reduced liver fat and AST levels, indicating a beneficial effect on liver health in patients with type 2 diabetes and NAFLD.
Indexed as
Identifiers
41579253What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.